CN108936630A - 一种霍山石斛姜黄葛根胶囊及制备方法 - Google Patents
一种霍山石斛姜黄葛根胶囊及制备方法 Download PDFInfo
- Publication number
- CN108936630A CN108936630A CN201810892031.0A CN201810892031A CN108936630A CN 108936630 A CN108936630 A CN 108936630A CN 201810892031 A CN201810892031 A CN 201810892031A CN 108936630 A CN108936630 A CN 108936630A
- Authority
- CN
- China
- Prior art keywords
- dendrobidium huoshanness
- parts
- turmeric
- radix puerariae
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 44
- 235000003392 Curcuma domestica Nutrition 0.000 title claims abstract description 27
- 235000003373 curcuma longa Nutrition 0.000 title claims abstract description 27
- 235000013976 turmeric Nutrition 0.000 title claims abstract description 27
- 244000008991 Curcuma longa Species 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 38
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 35
- 235000012754 curcumin Nutrition 0.000 claims abstract description 19
- 229940109262 curcumin Drugs 0.000 claims abstract description 19
- 239000004148 curcumin Substances 0.000 claims abstract description 19
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000000463 material Substances 0.000 claims abstract description 11
- 239000000314 lubricant Substances 0.000 claims abstract description 8
- 241000219781 Pueraria montana var. lobata Species 0.000 claims description 34
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 239000002245 particle Substances 0.000 claims description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 12
- 235000019441 ethanol Nutrition 0.000 claims description 12
- 238000011049 filling Methods 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- 239000011122 softwood Substances 0.000 claims description 12
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 229920002472 Starch Polymers 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000000080 wetting agent Substances 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 238000011068 loading method Methods 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 239000011265 semifinished product Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 235000020985 whole grains Nutrition 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-ASMJPISFSA-N alpha-maltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-ASMJPISFSA-N 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 238000005429 filling process Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 239000013049 sediment Substances 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 239000007779 soft material Substances 0.000 claims 1
- 235000009508 confectionery Nutrition 0.000 abstract description 11
- 210000004185 liver Anatomy 0.000 abstract description 9
- 239000000796 flavoring agent Substances 0.000 abstract description 7
- 235000019634 flavors Nutrition 0.000 abstract description 7
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 abstract description 4
- 239000000470 constituent Substances 0.000 abstract description 4
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 abstract description 4
- 206010061598 Immunodeficiency Diseases 0.000 abstract description 3
- 230000001914 calming effect Effects 0.000 abstract description 3
- 230000007123 defense Effects 0.000 abstract description 3
- 230000001717 pathogenic effect Effects 0.000 abstract description 3
- 238000005728 strengthening Methods 0.000 abstract description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 2
- 244000046146 Pueraria lobata Species 0.000 abstract 1
- 230000006378 damage Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 6
- 230000002440 hepatic effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 244000163122 Curcuma domestica Species 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000013219 diaphoresis Diseases 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000019581 fat taste sensations Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 231100000437 hepatocellular injury Toxicity 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000009955 starching Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种霍山石斛姜黄葛根胶囊及制备方法,由下述重量份数的组分组成:霍山石斛提取物1‑3份、葛根提取物3‑7份、姜黄素1.5‑4份、辅料1‑3份、润滑剂0.02‑0.1份;全方配合,甘润平和,滋阴益阳,阴中求阳,则阳得阴助生化无穷,阳中求阴,则阴得阳升而泉源不竭;又平肝泄热,升发清阳,共调人体机能状态,从而扶正祛邪,调动人体的防卫作用,共达保肝护肝的目的,对免疫力低下者有很好的保健功效。本发明还提供了所述霍山石斛组方胶囊的制备方法,由上述组方与辅料制成的胶囊剂,活性成分粗多糖(以无水葡萄糖计)≥1100mg/100g,葛根素≥460mg/100g,姜黄素≥10000mg/100g。
Description
技术领域
本发明属于保健食品制备技术领域,具体涉及一种霍山石斛姜黄葛根胶囊及制备方法。
背景技术
肝细胞损伤主要是由于毒物进入肝细胞内,经代谢产生大量自由基,引起脂质过氧化反应,导致细胞膜结构破坏,引起细胞坏死。①体内产生的自由基作用于内质网膜,使膜磷脂的不饱和和多脂肪酸发生过氧化,从而使内质网膜和细胞膜破坏;②自由基与肝细胞内的蛋白质、核酸等大分子物质发生不可逆共价结合,导致肝细胞坏死;③随后SOD活力下降,血清谷丙转氨酶进一步显著上升,自由基清除功能受损和脂质过氧化作用增强;④胞浆内Ca2+浓度升高,从而引起核糖体解聚,蛋白质合成减低,导致细胞死亡。
大部分化学性肝损伤是由酒精引起,包括轻症酒精性肝病、酒精性脂肪肝、酒精性肝炎、酒精性肝纤维化等。随着社会的发展和生活水平的提高,我国酒精消费群体日益增长,化学性肝损伤人群也在不断增加,因此开发具有辅助保护化学性肝损伤的保健食品具有广阔的市场前景。
霍山石斛味甘,滋养肝阴;葛根性凉味甘,清热生津解表;姜黄,性温味苦;全方配合,甘润平和,滋阴益阳,阴中求阳,则阳得阴助生化无穷,阳中求阴,则阴得阳升而泉源不竭;又平肝泄热,升发清阳,共调人体机能状态,从而扶正祛邪,调动人体的防卫作用,共达保肝护肝的目的,还对免疫力低下者有很好的保健功效。
然而现有的保护化学性肝损伤的保健食品中有效成分含量低,保健功效得不到充分发挥。
发明内容
本发明所要解决的技术问题在于:针对数量不断上升的化学性肝损伤人群,以及现有的保护化学性肝损伤的保健食品中有效成分含量低,保健功效得不到充分发挥的技术问题,提供了一种霍山石斛姜黄葛根胶囊及制备方法。
本发明采用以下技术方案解决上述技术问题:
一种霍山石斛姜黄葛根胶囊,由下述重量份数的组分组成:霍山石斛提取物1-3份、葛根提取物3-7份、姜黄素1.5-4份、辅料1-3份、润滑剂0.02-0.1份。
进一步,所述的霍山石斛提取物的制备方法为:
(1)将霍山石斛干条粉碎过60-100目,加6-14倍量水于90-100℃下煎煮提取2-5次,每次2-8小时,合并过滤;
(2)将步骤(1)所得滤液在-0.07~-0.09MPa压力下减压浓缩至相对密度1.1-1.2g/mL,得霍山石斛稠膏;
(3)将步骤(2)所得霍山石斛稠膏在60±5℃下干燥,得霍山石斛干浸膏,然后粉碎过60-100目筛,即得。
进一步,所述葛根提取物的制备方法为:
(1)将葛根粉碎过60-100目筛,加6-10倍量的70%乙醇回流提取2-4次,每次1-3小时,过滤,合并滤液;
(2)将步骤(1)所得滤液在-0.07~-0.09MPa压力下减压浓缩至相对密度1.1-1.2g/mL,得葛根稠膏;
(3)将步骤(2)所得葛根稠膏在60±5℃下干燥,得葛根干浸膏,然后粉碎过60-100目筛,即得。
进一步,所述姜黄素为市售,纯度≥90%。
进一步,所述的辅料为:淀粉、糊精、乳糖、微晶纤维素、淀粉糊精混合物(1∶1)、淀粉乳糖混合物(1∶1)中的任意一种或多种。
进一步,所述的辅料为淀粉或乳糖。
进一步,所述的润滑剂为:硬脂酸镁、滑石粉、微粉硅胶中的任意一种或多种。
进一步,所述的一种霍山石斛姜黄葛根胶囊,由下述重量份数的组分组成:霍山石斛提取物1份、葛根提取物5份、姜黄素1.96份、淀粉2份、硬脂酸镁0.04份。
进一步,所述的一种霍山石斛姜黄葛根胶囊,由下述重量份数的组分组成:霍山石斛提取物1.5份、葛根提取物5.5份、姜黄素1.7份、乳糖1.25份、硬脂酸镁0.05份。
进一步,所述的一种霍山石斛姜黄葛根胶囊的制备方法,包括以下步骤:
(1)配料:将霍山石斛提取物、葛根提取物、姜黄素、辅料分别粉碎过80-100目筛并按照配方量称量;
(2)混合:将称取的原辅料置混合机中混合20-30min,混合均匀;
(3)制粒:将混合好的原辅料加适量的75-85%乙醇作润湿剂制软材,边加边搅拌,使软材达到手握成团一触即散为宜;将制好的软材加入到制粒机中,16目制粒;将制好的湿颗粒置干燥设备内50-55℃条件下干燥90-120min,控制水分3-5%;将干燥好的颗粒置快速整粒机中过30目筛整粒,制备大小均一的颗粒;
(4)总混:将制好的颗粒与润滑剂置三维运动混合机中混合10-15min,使之混合均匀;
(5)填充:用胶囊填充机填充胶囊,每粒胶囊内容物0.25g,填充过程中应注意监测产品装量差异,使之控制在差异范围内;
(6)内包装:将检验合格后的胶囊,按规定的装量包装,将包装好的半成品移出控制区;包装环境要求温度控制在18-26℃,湿度在45-65%。
本发明技术有益效果:本发明从肝损伤的产生机理出发,以霍山石斛、葛根、姜黄组方,达到保肝护肝的效果同时,能够增加人体免疫力,方中霍山石斛味甘,滋养肝阴;葛根性凉味甘,清热生津解表;姜黄,性温味苦;全方配合,甘润平和,滋阴益阳,阴中求阳,则阳得阴助生化无穷,阳中求阴,则阴得阳升而泉源不竭;又平肝泄热,升发清阳,共调人体机能状态,从而扶正祛邪,调动人体的防卫作用,共达保肝护肝的目的,对免疫力低下者有很好的保健功效,具有促进脾淋巴细胞增殖、转化作用;促进抗体生成细胞增殖;提高血清融血素水平;促进单核-巨噬细胞碳廓清功能和腹腔巨噬细胞的吞噬能力;提高自然杀伤细胞活性。在对化学性肝损伤的保护方面:具有降低酒精性损伤的肝组织中过氧化脂质降解产物丙二醛和甘油三脂含量的作用;提高肝组织中还原型谷胱甘肽含量的作用;减轻酒精性肝损伤的肝组织脂肪变性的作用。
本发明还提供了所述霍山石斛组方胶囊的制备方法,将霍山石斛干条和葛根粉碎后分别利用水浸提和醇提再经减压浓缩后干燥制得霍山石斛提取物和葛根提取物,提取率高,有效成分和营养物质充分释放;采用75%乙醇作润湿剂制软材,和传统的以水作润滑剂相比,具有挥发快,所需干燥温度低,干燥时间短,具有节能降耗的优点。
由上述组方与辅料制成的胶囊剂,活性成分粗多糖(以无水葡萄糖计)≥1100mg/100g,葛根素≥460mg/100g,姜黄素≥10000mg/100g。
附图说明
图1为本发明实施例所述一种霍山石斛姜黄葛根胶囊的制备工艺流程图;
图2为本发明实施例所述霍山石斛提取物制备工艺流程图;
图3为本发明实施例所述葛根提取物制备工艺流程图。
具体实施方式
为便于本领域技术人员理解本发明技术方案,现结合说明书附图对本发明技术方案做进一步的说明。
实施例1
一种霍山石斛姜黄葛根胶囊,其配方为:霍山石斛提取物10kg、葛根提取物50kg、90%姜黄素19.6kg、淀粉20kg、硬脂酸镁0.4kg。
参阅图2,所述的霍山石斛提取物的制备方法为:
(1)将霍山石斛干条粉碎过60-100目,加6-14倍量水于90-100℃下煎煮提取2-5次,每次2-8小时,合并过滤;
(2)将步骤(1)所得滤液在-0.07~-0.09MPa压力下减压浓缩至相对密度1.1-1.2g/mL,得霍山石斛稠膏;
(3)将步骤(2)所得霍山石斛稠膏在60±5℃下干燥,得霍山石斛干浸膏,然后粉碎过60-100目筛,即得。
参阅图3,所述葛根提取物的制备方法为:
(1)将葛根粉碎过60-100目筛,加6-10倍量的70%乙醇回流提取2-4次,每次1-3小时,过滤,合并滤液;
(2)将步骤(1)所得滤液在-0.07~-0.09MPa压力下减压浓缩至相对密度1.1-1.2g/mL,得葛根稠膏;
(3)将步骤(2)所得葛根稠膏在60±5℃下干燥,得葛根干浸膏,然后粉碎过60-100目筛,即得。
参阅图1,所述的一种霍山石斛姜黄葛根胶囊的制备方法,包括以下步骤:
(1)配料:将霍山石斛提取物、葛根提取物、90%姜黄素、淀粉分别粉碎过80目筛并按照配方量称量;
(2)混合:将称取的原辅料置混合机中混合20min,混合均匀;
(3)制粒:将混合好的原辅料加适量的75%乙醇作润湿剂制软材,边加边搅拌,使软材达到手握成团一触即散为宜;将制好的软材加入到制粒机中,16目制粒;将制好的湿颗粒置干燥设备内55℃条件下干燥90-120min,控制水分3-5%;将干燥好的颗粒置快速整粒机中过30目筛整粒,制备大小均一的颗粒;
(4)总混:将制好的颗粒与0.4kg硬脂酸镁置三维运动混合机中混合10min,使之混合均匀;
(5)填充:用胶囊填充机填充胶囊,每分钟填充1000粒,每粒胶囊内容物0.25g,填充过程中每10min检测装量差异,使之控制在0.25g±10%范围内;
(6)内包装:将检验合格后的胶囊,按规定的装量包装,将包装好的半成品移出控制区;包装环境要求温度控制在18-26℃,湿度在45-65%。
制备的样品经检测粗多糖1230mg/100g,葛根素518mg/100g,姜黄素16311mg/100g。
实施例2
一种霍山石斛姜黄葛根胶囊,其配方为:霍山石斛提取物15kg、葛根提取物55kg、95%姜黄素17kg、乳糖12.5kg、硬脂酸镁0.5kg。
参阅图2,所述的霍山石斛提取物的制备方法为:
(1)将霍山石斛干条粉碎过60-100目,加6-14倍量水于90-100℃下煎煮提取2-5次,每次2-8小时,合并过滤;
(2)将步骤(1)所得滤液在-0.07~-0.09MPa压力下减压浓缩至相对密度1.1-1.2g/mL,得霍山石斛稠膏;
(3)将步骤(2)所得霍山石斛稠膏在60±5℃下干燥,得霍山石斛干浸膏,然后粉碎过60-100目筛,即得。
参阅图3,所述葛根提取物的制备方法为:
(1)将葛根粉碎过60-100目筛,加6-10倍量的70%乙醇回流提取2-4次,每次1-3小时,过滤,合并滤液;
(2)将步骤(1)所得滤液在-0.07~-0.09MPa压力下减压浓缩至相对密度1.1-1.2g/mL,得葛根稠膏;
(3)将步骤(2)所得葛根稠膏在60±5℃下干燥,得葛根干浸膏,然后粉碎过60-100目筛,即得。
参阅图1,所述的一种霍山石斛姜黄葛根胶囊的制备方法,包括以下步骤:
(1)配料:将霍山石斛提取物、葛根提取物、95%姜黄素、乳糖分别粉碎过80目筛并按照配方量称量;
(2)混合:将称取的原辅料置混合机中混合20min,混合均匀;
(3)制粒:将混合好的原辅料加适量的75%乙醇作润湿剂制软材,边加边搅拌,使软材达到手握成团一触即散为宜;将制好的软材加入到制粒机中,16目制粒;将制好的湿颗粒置干燥设备内55℃条件下干燥90-120min,控制水分3-5%;将干燥好的颗粒置快速整粒机中过30目筛整粒,制备大小均一的颗粒;
(4)总混:将制好的颗粒与0.5kg硬脂酸镁置三维运动混合机中混合10min,使之混合均匀;
(5)填充:用胶囊填充机填充胶囊,每分钟填充1000粒,每粒胶囊内容物0.25g,填充过程中每10min检测装量差异,使之控制在0.25g±10%范围内;
(6)内包装:将检验合格后的胶囊,按规定的装量包装,将包装好的半成品移出控制区;包装环境要求温度控制在18-26℃,湿度在45-65%。
制备的样品经检测粗多糖1560mg/100g,葛根素678mg/100g,姜黄素14132mg/100g。
Claims (10)
1.一种霍山石斛姜黄葛根胶囊,其特征在于,由下述重量份数的组分组成:霍山石斛提取物1-3份、葛根提取物3-7份、姜黄素1.5-4份、辅料1-3份、润滑剂0.02-0.1份。
2.根据权利要求1所述的一种霍山石斛姜黄葛根胶囊,其特征在于,所述的霍山石斛提取物的制备方法为:
(1)将霍山石斛干条粉碎过60-100目,加6-14倍量水于90-100℃下煎煮提取2-5次,每次2-8小时,合并过滤;
(2)将步骤(1)所得滤液在-0.07~-0.09MPa压力下减压浓缩至相对密度1.1-1.2g/mL,得霍山石斛稠膏;
(3)将步骤(2)所得霍山石斛稠膏在60±5℃下干燥,得霍山石斛干浸膏,然后粉碎过60-100目筛,即得。
3.根据权利要求1所述的一种霍山石斛姜黄葛根胶囊,其特征在于,所述葛根提取物的制备方法为:
(1)将葛根粉碎过60-100目筛,加6-10倍量的70%乙醇回流提取2-4次,每次1-3小时,过滤,合并滤液;
(2)将步骤(1)所得滤液在-0.07~-0.09MPa压力下减压浓缩至相对密度1.1-1.2g/mL,得葛根稠膏;
(3)将步骤(2)所得葛根稠膏在60±5℃下干燥,得葛根干浸膏,然后粉碎过60-100目筛,即得。
4.根据权利要求1所述的一种霍山石斛姜黄葛根胶囊,其特征在于,所述姜黄素为市售,纯度≥90%。
5.根据权利要求1所述的一种霍山石斛姜黄葛根胶囊,其特征在于,所述的辅料为:淀粉、糊精、乳糖、微晶纤维素、淀粉糊精混合物(1∶1)、淀粉乳糖混合物(1∶1)中的任意一种或多种。
6.根据权利要求5所述的一种霍山石斛姜黄葛根胶囊,其特征在于,所述的辅料为淀粉或乳糖。
7.根据权利要求1所述的一种霍山石斛姜黄葛根胶囊,其特征在于,所述的润滑剂为:硬脂酸镁、滑石粉、微粉硅胶中的任意一种或多种。
8.根据权利要求1所述的一种霍山石斛姜黄葛根胶囊,其特征在于,由下述重量份数的组分组成:霍山石斛提取物1份、葛根提取物5份、姜黄素1.96份、淀粉2份、硬脂酸镁0.04份。
9.根据权利要求1所述的一种霍山石斛姜黄葛根胶囊,其特征在于,由下述重量份数的组分组成:霍山石斛提取物1.5份、葛根提取物5.5份、姜黄素1.7份、乳糖1.25份、硬脂酸镁0.05份。
10.一种制备权利要求1-9任意一项所述的霍山石斛姜黄葛根胶囊的方法,其特征在于,包括以下步骤:
(1)配料:将霍山石斛提取物、葛根提取物、姜黄素、辅料分别粉碎过80-100目筛并按照配方量称量;
(2)混合:将称取的原辅料置混合机中混合20-30min,混合均匀;
(3)制粒:将混合好的原辅料加适量的75-85%乙醇作润湿剂制软材,边加边搅拌,使软材达到手握成团一触即散为宜;将制好的软材加入到制粒机中,16目制粒;将制好的湿颗粒置干燥设备内50-55℃条件下干燥90-120min,控制水分3-5%;将干燥好的颗粒置快速整粒机中过30目筛整粒,制备大小均一的颗粒;
(4)总混:将制好的颗粒与润滑剂置三维运动混合机中混合10-15min,使之混合均匀;
(5)填充:用胶囊填充机填充胶囊,每粒胶囊内容物0.25g,填充过程中应注意监测产品装量差异,使之控制在差异范围内;
(6)内包装:将检验合格后的胶囊,按规定的装量包装,将包装好的半成品移出控制区;包装环境要求温度控制在18-26℃,湿度在45-65%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810892031.0A CN108936630A (zh) | 2018-08-07 | 2018-08-07 | 一种霍山石斛姜黄葛根胶囊及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810892031.0A CN108936630A (zh) | 2018-08-07 | 2018-08-07 | 一种霍山石斛姜黄葛根胶囊及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108936630A true CN108936630A (zh) | 2018-12-07 |
Family
ID=64468037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810892031.0A Pending CN108936630A (zh) | 2018-08-07 | 2018-08-07 | 一种霍山石斛姜黄葛根胶囊及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108936630A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113616739A (zh) * | 2021-08-17 | 2021-11-09 | 皖西学院 | 一种霍山铁皮石斛软胶囊及其制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101444303A (zh) * | 2008-12-10 | 2009-06-03 | 陶国闻 | 石斛葛根杜仲功能食品 |
CN102266491A (zh) * | 2011-07-15 | 2011-12-07 | 安徽圣农生物科技股份有限公司 | 一种复方霍山石斛浸膏的配方及生产工艺 |
CN102512600A (zh) * | 2011-12-13 | 2012-06-27 | 常熟雷允上制药有限公司 | 一种具有保肝作用的保健品及其制备方法 |
CN102727759A (zh) * | 2012-06-29 | 2012-10-17 | 常州亚当生物技术有限公司 | 一种解酒保肝的姜黄素-铁皮石斛复合物及其制备方法 |
CN103446451A (zh) * | 2013-09-16 | 2013-12-18 | 贵州仙草生物科技有限公司 | 一种对酒精性肝损伤有保护功能的金钗石斛丸及其制备方法 |
CN106362004A (zh) * | 2016-10-31 | 2017-02-01 | 海南葫芦娃药业集团股份有限公司 | 一种复方鲜石斛颗粒及其制备方法 |
CN106376927A (zh) * | 2016-08-25 | 2017-02-08 | 苏州神元生物科技股份有限公司 | 一种对化学性肝损伤具有辅助保护作用的保健品 |
-
2018
- 2018-08-07 CN CN201810892031.0A patent/CN108936630A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101444303A (zh) * | 2008-12-10 | 2009-06-03 | 陶国闻 | 石斛葛根杜仲功能食品 |
CN102266491A (zh) * | 2011-07-15 | 2011-12-07 | 安徽圣农生物科技股份有限公司 | 一种复方霍山石斛浸膏的配方及生产工艺 |
CN102512600A (zh) * | 2011-12-13 | 2012-06-27 | 常熟雷允上制药有限公司 | 一种具有保肝作用的保健品及其制备方法 |
CN102727759A (zh) * | 2012-06-29 | 2012-10-17 | 常州亚当生物技术有限公司 | 一种解酒保肝的姜黄素-铁皮石斛复合物及其制备方法 |
CN103446451A (zh) * | 2013-09-16 | 2013-12-18 | 贵州仙草生物科技有限公司 | 一种对酒精性肝损伤有保护功能的金钗石斛丸及其制备方法 |
CN106376927A (zh) * | 2016-08-25 | 2017-02-08 | 苏州神元生物科技股份有限公司 | 一种对化学性肝损伤具有辅助保护作用的保健品 |
CN106362004A (zh) * | 2016-10-31 | 2017-02-01 | 海南葫芦娃药业集团股份有限公司 | 一种复方鲜石斛颗粒及其制备方法 |
Non-Patent Citations (4)
Title |
---|
王丽平: "《保健食品GMP实用指南》", 30 April 2007, 中国轻工业出版社 * |
王凯等: "5种石斛对四氯化碳致小鼠急性肝损伤的保护作用", 《中国中药杂志》 * |
解酒护肝片: "姜黄葛根胶囊", 《美健品招商网》 * |
钱明雪等: "6种石斛多糖抗亚急性酒精性肝损伤作用的比较", 《中国药学杂志》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113616739A (zh) * | 2021-08-17 | 2021-11-09 | 皖西学院 | 一种霍山铁皮石斛软胶囊及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101897440B (zh) | 辅酶q10复合软胶囊及其制备方法 | |
CN104171328A (zh) | 一种富硒中草药发酵山羊饲料 | |
CN101313756A (zh) | 一种保健食品的制备方法 | |
CN101999713B (zh) | 一种螺旋藻片及其制备方法 | |
CN109349673A (zh) | 一种南极磷虾油软胶囊囊皮、软胶囊及其制备方法 | |
CN104922167A (zh) | 一种灵芝孢子粉冲剂及其制备方法 | |
CN104549084B (zh) | 复合微胶囊壁材及微胶囊和制备方法 | |
CN108936630A (zh) | 一种霍山石斛姜黄葛根胶囊及制备方法 | |
CN109007260A (zh) | 提高鲟鱼免疫力的饲料及其制备方法 | |
CN102188407A (zh) | 一种复方中药微胶囊的制备方法 | |
CN104605346B (zh) | 一种面粉及其制备方法 | |
CN104664386A (zh) | 超微粉玛咖片 | |
CN101991113A (zh) | 一种海参油软胶囊及其制备方法 | |
CN105166273B (zh) | 一种牡丹籽油糖块及其制备方法 | |
CN108823018A (zh) | 红枣特酿及加工工艺 | |
CN104055819B (zh) | 一种菊花破壁制剂 | |
CN107753323A (zh) | 一种泥炭面膜泥及其制备方法 | |
CN102836380B (zh) | 一种含中药的蚂蚁水丸及其制备方法 | |
CN104623099A (zh) | 一种对化学性肝损伤有辅助保护作用的保健品 | |
CN104982899A (zh) | 一种蜂蜜芝麻酱及其制备方法 | |
CN104543820A (zh) | 红枣酥及其制造方法 | |
CN104783177A (zh) | 玛咖汉子 | |
CN109924345A (zh) | 一种利用中药残渣制备的海参饲料预混剂及其制备方法 | |
CN108835371A (zh) | 鲟鱼饲料及其制备方法 | |
CN108323762A (zh) | 一种富硒组合物及制剂,其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181207 |
|
RJ01 | Rejection of invention patent application after publication |